Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non–Small-cell Lung Cancer
2018 · Clinical Lung Cancer · 143 citations
https://doi.org/10.1016/j.cllc.2018.08.008
M
Miguel A. Villalona‐Calero
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
352
Papers
9.0K
Citations
47
h-index
116
i10-index
Miguel A. Villalona‐Calero is an academic researcher from City Of Hope National Medical Center. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Treatment and Pharmacology & Cancer Genomics and Diagnostics. The author has an h-index of 47, co-authored 300 publications.
ORCID: 0000-0002-1991-5070Papers by this author
worksResults of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
2015 · Scientific Reports · 78 citations
https://doi.org/10.1038/srep12122
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
2018 · Investigational New Drugs · 15 citations
https://doi.org/10.1007/s10637-018-0630-9
604O Phase I dose escalation and initial dose expansion results of AMG 193: A MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors
2024 · Annals of Oncology · 9 citations
https://doi.org/10.1016/j.annonc.2024.08.671
Interim report on engineered NK cell trial in lung cancer refractory to immune checkpoint inhibitors
2025 · JCI Insight · 8 citations
https://doi.org/10.1172/jci.insight.186890
Abstract 5586: Phase I study of PARP inhibitor ABT-888 and carboplatin with novel imaging in metastatic breast cancer (MBC) (NCI-8609)
2012 · Cancer Research · 0 citations
https://doi.org/10.1158/1538-7445.am2012-5586
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat